Stay updated on DONATE Study: Dapagliflozin Safety in T2DM Clinical Trial
Sign up to get notified when there's something new on the DONATE Study: Dapagliflozin Safety in T2DM Clinical Trial page.

Latest updates to the DONATE Study: Dapagliflozin Safety in T2DM Clinical Trial page
- CheckyesterdayChange DetectedRevision updated from v3.3.3 to v3.3.4; no changes to core study content, eligibility criteria, outcomes, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe Locations section was reorganized to add a top-level Locations header and individual province/municipality subsections (Anhui, Beijing Municipality, Chongqing Municipality, etc.), replacing the previous per-location headers.SummaryDifference2%

- Check30 days agoChange DetectedAdded 'Type 2 diabetes' as a study topic tag. Added 'MedlinePlus Genetics' as a related topic.SummaryDifference0.1%

- Check37 days agoChange DetectedThe page removes the condition 'Type 2 Diabetes Mellitus' from the study description and related topics, and the related topic 'MedlinePlus Genetics' is removed.SummaryDifference0.1%

- Check52 days agoChange DetectedPublications section now states publications are automatically filled from PubMed, and the revision label changed from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check59 days agoChange DetectedThe page removed the banner noting a lapse in government funding and the NIH operating status. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to DONATE Study: Dapagliflozin Safety in T2DM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the DONATE Study: Dapagliflozin Safety in T2DM Clinical Trial page.